Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA vs. IncobotulinumtoxinA in Chronic Migraine
NCT05598723Phase 3Recruiting
- Sponsor
- Naval Medical Center Camp Lejeune
- Start
- Feb 2023
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in chronic migraine, sponsored by Naval Medical Center Camp Lejeune. Started Feb 2023; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT05598723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598723.